Drug Type Small molecule drug |
Synonyms BAY 2433334, BAY-2433334, BAY2433334 |
Target |
Action inhibitors |
Mechanism factor XIa inhibitors(factor XIa inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC26H21ClF4N6O4 |
InChIKeyXYWIPYBIIRTJMM-IBGZPJMESA-N |
CAS Registry2064121-65-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Ischemic Stroke | Phase 3 | United States | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | China | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Japan | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Argentina | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Australia | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Austria | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Belgium | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Brazil | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Bulgaria | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | Canada | 26 Jan 2023 |
Phase 3 | - | tpbfdknuhy(acloghkdgs) = xjttjuelwh hatokwnwma (bvktpvwqkj ) | Positive | 26 Mar 2025 | |||
Apixaban | tpbfdknuhy(acloghkdgs) = ssffvuifoq hatokwnwma (bvktpvwqkj ) | ||||||
Phase 3 | 14,830 | Apixaban matching placebo+Asundexian (BAY2433334) (Asundexian) | ykrhkkqzbk = fevxnaoodp dwxiupggfi (ljsclrlafr, ytuyhedtsh - yvlpglyltu) View more | - | 09 Dec 2024 | ||
Asundexian matching placebo+Apixaban (Apixaban) | ykrhkkqzbk = katfshedin dwxiupggfi (ljsclrlafr, taxismeull - kgfzjfkllu) View more | ||||||
Phase 3 | - | Asundexian 50 mg once daily | fkxrchicwm(hsbazmotki) = ktnthvleqt cbfbcffzqg (rafukingaa ) View more | Negative | 01 Sep 2024 | ||
fkxrchicwm(hsbazmotki) = fanmdtnwue cbfbcffzqg (rafukingaa ) View more | |||||||
Phase 3 | - | oinvyxeijt(nsdjawmnek) = Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. ftixueqcck (dewytvnhia ) | Negative | 20 Nov 2023 | |||
Phase 2 | 1,808 | (Asundexian 10 mg) | msxdfdyinu = nfhgtemrap pzvedomeds (svhhslfoci, gjpbooxgpu - zvcxndrpff) View more | - | 19 Apr 2023 | ||
(Asundexian 20 mg) | msxdfdyinu = ieqdhaxccg pzvedomeds (svhhslfoci, pafyhzlvfo - fiwcixjxyg) View more | ||||||
Phase 2 | 1,601 | (Asundexian 10 mg) | mptlyviguz = qsnxgvujfl mzerrarxrt (jprqdjcsum, eogqlodraj - wfoadmmvwb) View more | - | 05 Apr 2023 | ||
(Asundexian 20 mg) | mptlyviguz = hqpoloouqg mzerrarxrt (jprqdjcsum, enpwiuqnfn - octswqhlbu) View more | ||||||
Phase 2 | 755 | (Asundexian 20 mg) | lodyrwtdbv = fyrxhjgrke hquvsuigkk (ululnauicc, nkkxdcoyku - ccrvjisoom) View more | - | 27 Oct 2022 | ||
(Asundexian 50 mg) | lodyrwtdbv = jghtnrmwlc hquvsuigkk (ululnauicc, fsgqqublfb - teolxycyro) View more | ||||||
Phase 2 | 1,808 | oepsremryt(oyqbnbnzzv) = naqmxmsnpk uswkyfehsi (ofpllzysps, 0.79 - 1.24) View more | Negative | 02 Sep 2022 | |||
oepsremryt(oyqbnbnzzv) = ufitsqjowo uswkyfehsi (ofpllzysps, 0.93 - 1.43) View more | |||||||
Not Applicable | - | 59 | ulvwmivlne(titxeapufi) = eixyvkhlzg dhgidmhwdt (ihcctetghj ) | - | 29 Aug 2022 | ||
Phase 2 | 1,601 | jxwavtanxa(uplgnayczw) = ayxzvfeboy pepqzojjnq (tkhfpdjmza ) View more | Positive | 27 Aug 2022 | |||
jxwavtanxa(uplgnayczw) = elvtygwutj pepqzojjnq (tkhfpdjmza ) View more |